Nature and Biodiversity

The world's first vaccine for humans and livestock is being developed

Kenya Maasai Isaac Deka stands next to his three exhausted cows clustered under a thorny acacia tree near the Rift Valley town of Kajiado, 75 km (47 miles) south of Kenyan capital Nairobi, March 25, 2009. Cattle are the economic lifeblood of around 150,000 Maasai scattered in homesteads across Kenya's southern Rift Valley, but now they are dropping where they stand, their parched bodies stinking in the red dust. Picture taken on March 25, 2009. To match feature KENYA-DROUGHT/  REUTERS/Antony Njuguna (KENYA ENVIRONMENT ANIMALS) - GM1E53Q1JKM01

Scientists are working on a revolutionary vaccine for Rift Valley Fever which works on humans and animals. Image: REUTERS/Antony Njuguna

George Warimwe
Associate Professor, University of Oxford
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on Nature and Biodiversity?
The Big Picture
Explore and monitor how South Africa is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

South Africa

If ever there were proof that humans are animals too, it’s in the diseases that we share with other species. From rabies and Zika to Ebola and bird flu, many deadly diseases around the world can pass between animals and people.

Currently, we have three options when trying to protect people from such zoonotic diseases. We can vaccinate the animals that can pass them on, the humans that can contract them, or take steps to help the two avoid contact. But what if there were a simple, inexpensive way to protect both people and other species at the same time, using the same vaccine?

This was my starting point when I decided to investigate the possibility of a single cross-species vaccine for Rift Valley Fever, one of the World Health Organization’s priority diseases.

Image: ASTMH

Since emerging in Kenya in 1930, the mosquito-borne disease has spread to many African countries and the Arabian Peninsula, causing disease outbreaks that have affected millions of livestock and hundreds of thousands of humans.

During such outbreaks, the disease kills more than 90% of young animals and causes nearly 100% of pregnant animals to abort their foetuses. This can destroy livelihoods in largely agricultural societies. For example, an outbreak in Kenya in 2006 and 2007 cost the agricultural sector estimated losses of over US$32m, with profound social impacts among affected communities. In humans, the fever is less severe but can occasionally cause encephalitis, blindness, haemorrhage and even death.

Young livestock are particularly at risk from Rift Valley Fever. Image: George Warimwe/University of Oxford, Author provided

The most widely used animal vaccines are not recommended for pregnant animals due to risks of abortion and malformation, while there is currently no licensed vaccine readily available to protect humans from Rift Valley Fever. This leaves, farmers, animals, and their unborn offspring at risk.

Developing the vaccine

Since clinical trials are always the final stage in demonstrating that a vaccine is safe to use in humans, my colleagues and I started by using a technique that has extensively been shown to be safe for human vaccination against a host of diseases, including influenza, malaria, and Ebola.

The technique uses a chimpanzee respiratory virus (adenovirus) to expose individuals to just a small part of the Rift Valley Fever virus – enough for the immune system to recognise a future infection, but not enough to cause an infection in itself. As this incomplete virus is markedly different to the full virus, the technique allows animal health practitioners to accurately test whether an animal is vaccinated, or an infected but symptomless carrier. This is crucial during outbreaks, as false positives can lead to unnecessary culling of livestock, increased costs, and reduced cooperation of farmers in the fight to control the disease.

Have you read?

In our earlier studies, we found that a single dose of this vaccine, the first of its kind, provided 100% protection against Rift Valley Fever in multiple livestock species in Kenya. We expect the vaccine to perform equally well in livestock field trials, a key step in a vaccine’s journey towards widespread use. And because of our adenovirus technique, we also expect that it will pass human clinical trials planned for early next year.

This cross-species approach, known as “One Health”, is an underutilised tool in the development of vaccines against shared disease threats. By using advances in human vaccine research for the benefit of veterinary vaccines, and vice versa, researchers can better unlock the shared biological mechanisms underlying disease immunity, accelerating the design and development of vaccines across species.

This approach also saves time and money. Key differences in regulations between human and animal vaccine development mean that many aspects of what is actually a highly similar process are unnecessarily duplicated. By actively leveraging similarities between species, time-consuming technical hurdles at various stages of the vaccine development process can be leapfrogged, and the often extremely high costs of both development and production can be streamlined. And in producing a single vaccine, we would anticipate easier collaboration between human and animal health practitioners in controlling disease spread.

I am hopeful that this cross-species vaccine will pass human trials and pave the way for further treatments and immunisations in the One Health vein. At least 60% of all existing infectious diseases of humans originate with animals, and the One Health vaccine approach holds hope in the fight against many of them.

More than this, it may provide species other than our own a crucial line of defence against newly emerging deadly diseases. Vaccine development for sudden outbreaks of Ebola, for example, has tended to be frantic and human-focused, leaving a third of the world’s chimps and gorillas dead. With a One Health hat on, future vaccines may not just be a tool to protect human health, but biodiversity too.

Loading...
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
Nature and BiodiversityGeographies in DepthEconomic GrowthHealth and Healthcare Systems
Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Why nature-positive cities can help transform the planet

Carlos Correa Escaf

May 24, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum